ARA-290 Research Guide: Cibinetide, Innate Repair Receptor Evidence, COA, and Sourcing

Neuroscience Peptides | 2026-08-30 | 12 min read

An evidence-aware guide to ARA-290, also called cibinetide or pyroglutamate helix B surface peptide, covering innate repair receptor research, clinical-study limits, COA review, 10mg specifications, and sourcing.

ARA-290, ARA 290, and cibinetide

ARA-290 is a synthetic peptide derived from the three-dimensional structure of erythropoietin. The literature also uses ARA 290, cibinetide, and pyroglutamate helix B surface peptide. These terms help researchers find the relevant evidence, but a purchasing record should still identify the exact supplied sequence, chemical form, product code, and batch.

ARA-290 was designed to explore tissue-protective signaling without the erythropoietic activity associated with full-length erythropoietin. It is commonly discussed in neuropathy, inflammation, tissue-protection, and innate repair receptor research. Those research areas should not be converted into broad personal-use claims.

The innate repair receptor research model

The proposed research mechanism involves a receptor complex containing the erythropoietin receptor and the beta-common receptor, CD131. This complex is often called the innate repair receptor. Experimental studies use ARA-290 or cibinetide to investigate signaling related to cytoprotection, inflammation, and tissue repair.

Animal research has examined ARA-290 in nerve-injury and other tissue-damage models. Several exploratory and phase 2 studies also evaluated cibinetide in small-fiber neuropathy settings. These studies are useful parts of the evidence map, but they differ in population, endpoint, duration, and design. A catalog page should not imply that an investigational study makes the supplied research material an approved medicine.

How to read the human-study evidence

One randomized study evaluated corneal nerve fiber measures and neuropathy-related endpoints in people with sarcoidosis-associated small nerve fiber loss. Another small study explored metabolic and neuropathic variables in people with type 2 diabetes. These publications justify search terms such as ARA-290 clinical research and cibinetide small fiber neuropathy study, but they do not justify universal efficacy or safety claims.

The source, sequence, purity, formulation, and quality system used in a controlled study also cannot be assumed from a generic online product listing. Laboratory buyers must qualify the material they actually receive.

ARA-290 COA and identity review

A useful ARA-290 COA should link the exact peptide identity to a lot number and report measured results rather than marketing descriptions. HPLC can support purity assessment, and mass spectrometry can support molecular identity. Buyers may also need sequence confirmation, counterion information, water content, net peptide content, endotoxin data, or residual-solvent information depending on the intended laboratory method.

Key sourcing questions include:

• Does the document use ARA-290 and cibinetide consistently without confusing them with erythropoietin?
• Is the exact peptide sequence or molecular identity available for qualification?
• Do the vial label, quotation, and COA show the same product code and batch number?
• Are purity and identity supported by separate, named methods?
• Is the reported quantity gross vial content or net peptide content?
• Are counterion, storage, packaging, and shipping conditions documented?

The statement third-party tested is meaningful only when the report can be tied to the supplied lot and the analytical scope is visible.

Comparing ARA-290 10mg research supply

ZePeptide lists ARA 290 in a 10mg x 10-vial research format. Compare total material, vial count, batch documentation, analytical scope, and delivery terms before comparing headline prices. The spelling ARA290, ARA-290, or ARA 290 should not cause duplicate procurement records for the same qualified material.

For repeat projects, maintain lot-level records and define acceptance criteria before ordering. This protects comparability when a supplier changes counterion, water content, packaging, or release method.

ZePeptide supplies ARA-290 for lawful laboratory research only. This article does not provide medical advice, dosing, administration instructions, or a claim of approved therapeutic use.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.